World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Research Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 990-1010

POLYCYSTIC OVARY SYNDROME (PCOS) WITH PATHOPHYSIOLOGY AND EMERGING THERAPIES

Nahida Tabassum*[1] and Rameshwar Kumar[2]

[1,2]Faculty of Krishna Institute of Nursing & Paramedical Science, Samastipur, Bihar.

Article Received: 30 July 2025 | | Article Revised: 20 August 2025 | | Article Accepted: 10 September 2025

***Corresponding Author: Nahida Tabassum**
Faculty of Krishna Institute of Nursing & Paramedical Science, Samastipur, Bihar.
DOI: https://doi.org/10.5281/zenodo.17122529

How to cite this Article: Nahida Tabassum, Rameshwar Kumar (2025) POLYCYSTIC OVARY SYNDROME (PCOS) WITH PATHOPHYSIOLOGY AND EMERGING THERAPIES. World Journal of Pharmaceutical Science and Research, 4(4), 990-1010. https://doi.org/10.5281/zenodo.17122529

ABSTRACT

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder that affects approximately 8–13% of women of reproductive age worldwide, depending on the diagnostic criteria and population studied.[1] Clinically, it is defined by the presence of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, after exclusion of other related conditions.[2] PCOS is associated with significant reproductive, metabolic, and psychological complications, extending far beyond fertility concerns. Insulin resistance, present even in lean phenotypes, plays a central role in amplifying hyperandrogenism and disrupting folliculogenesis, ultimately leading to chronic anovulation.[3] This interplay contributes to long-term consequences including obesity, type 2 diabetes mellitus, dyslipidaemia, cardiovascular risk, and an increased likelihood of endometrial pathology.[4] Over the past decade, advances in research and international guideline updates have shaped the diagnostic framework and therapeutic strategies for PCOS. The 2023 International Evidence-Based Guideline reaffirmed the Rotterdam criteria for adults, clarified adolescent diagnostic parameters, and emphasized the role of anti-Müllerian hormone (AMH) as a marker of polycystic ovarian morphology in adults, but not as a stand-alone diagnostic test.[5] Management continues to rely on lifestyle modification as the cornerstone of therapy, combined oral contraceptives for cycle regulation and hyperandrogenism, and letrozole as first-line pharmacological treatment for anovulatory infertility. Metformin remains an important adjunct for insulin resistance and metabolic risk reduction. In recent years, novel pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated promise in improving metabolic parameters and weight management, though further large-scale studies are required to confirm their long-term safety and reproductive benefits. This review explores the pathophysiological mechanisms underlying PCOS, synthesizes existing literature, and evaluates current and emerging therapeutic options with a focus on clinical translation and future research directions.

KEYWORDS: Polycystic ovary syndrome, hyperandrogenism, insulin resistance, fertility, emerging therapies.

INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most common and complex endocrine disorders in women, encompassing a constellation of reproductive, metabolic, and psychological disturbances. It affects an estimated 8–13% of women of reproductive age globally, though the prevalence varies significantly depending on the diagnostic criteria applied and the population under study.[6] Despite its recognition as a reproductive disorder for decades, PCOS has increasingly come to be understood as a systemic condition with multisystemic implications that extend throughout the lifespan. The syndrome is a major cause of anovulatory infertility, menstrual irregularities, and hyperandrogenic features such as hirsutism and acne. However, its impact is not confined to gynecological health: women with PCOS are also at heightened risk of insulin resistance, type 2 diabetes mellitus, dyslipidemia, cardiovascular disease, and mental health concerns, rendering the disorder a pressing public health issue.[7]

The clinical definition of PCOS has evolved considerably over the last century. In 1935, Stein and Leventhal first reported a cluster of patients presenting with amenorrhea, infertility, and bilaterally enlarged polycystic ovaries, laying the foundation for the recognition of this syndrome.[8] Since then, diagnostic frameworks have developed in response to emerging clinical and research insights. The National Institutes of Health (NIH) consensus in 1990 emphasized chronic anovulation and hyperandrogenism as essential diagnostic criteria. The subsequent Rotterdam consensus in 2003 broadened the definition to include polycystic ovarian morphology on ultrasound as one of three diagnostic features, of which two must be present for diagnosis. More recently, the 2023 International Evidence-Based Guideline reaffirmed the use of the Rotterdam criteria for adults, while providing clarity for adolescent diagnosis and discouraging the use of anti-Müllerian hormone (AMH) levels as a sole diagnostic marker.[9] These refinements highlight the ongoing debate regarding phenotypic heterogeneity and the challenge of balancing diagnostic sensitivity with specificity.

Epidemiology and Global Burden

The prevalence of PCOS is highly dependent on the criteria used. Studies employing the NIH definition, which requires both hyperandrogenism and ovulatory dysfunction, report prevalence rates closer to 6–8%, whereas the Rotterdam criteria yield higher estimates of 12–13% due to the inclusion of polycystic ovarian morphology as an alternative feature.[6] Regional variations are also observed, with higher prevalence in South Asian and Middle Eastern populations compared with European and East Asian cohorts. These disparities may be attributable to genetic predisposition, environmental factors, lifestyle patterns, and differences in diagnostic methodology.

From a public health perspective, the global burden of PCOS is significant. The disorder contributes disproportionately to infertility-related healthcare utilization, particularly in settings where access to assisted reproductive technologies is limited. Moreover, the metabolic consequences of PCOS add to the global burden of non-communicable diseases (NCDs). Women with PCOS are up to four times more likely to develop type 2 diabetes mellitus, particularly when compounded by obesity and sedentary lifestyle.[10] Cardiovascular morbidity and mortality are less well established but emerging evidence suggests a trajectory of increased risk factors, including hypertension, dyslipidemia, and subclinical atherosclerosis.

Beyond physical health, the socioeconomic impact of PCOS is considerable. The syndrome imposes a significant financial burden on healthcare systems, arising from long-term management of reproductive, metabolic, and psychological complications. In the United States alone, the estimated annual cost of PCOS, including diagnosis, reproductive interventions, and management of metabolic consequences, exceeds several billion dollars. For

individuals, the disorder often entails recurrent healthcare visits, use of fertility services, cosmetic interventions for hyperandrogenism, and psychological support, all of which add to personal and familial costs.

Pathophysiological Complexity

At its core, PCOS is a disorder of disrupted ovarian function intertwined with metabolic dysregulation. Hyperandrogenism is both a defining feature and a central driver of pathophysiology, leading to hirsutism, acne, and ovulatory dysfunction. Insulin resistance, present in up to 70% of women with PCOS irrespective of body mass index, exacerbates hyperandrogenism by stimulating ovarian theca cell androgen production and suppressing hepatic sex hormone-binding globulin (SHBG) synthesis. This results in elevated circulating free androgens, which perpetuate follicular arrest and anovulation.

The neuroendocrine axis also plays a pivotal role. Many women with PCOS exhibit increased pulsatile secretion of gonadotropin-releasing hormone (GnRH), leading to elevated luteinizing hormone (LH) levels and an increased LH/follicle-stimulating hormone (FSH) ratio. This hormonal milieu favors androgen production over follicular maturation, further contributing to anovulation. Importantly, these abnormalities are not uniform across all phenotypes, underscoring the heterogeneity of the disorder.

Emerging research highlights the multifactorial etiology of PCOS, implicating genetic susceptibility, intrauterine environmental exposures, and lifestyle influences. Genome-wide association studies (GWAS) have identified susceptibility loci associated with gonadotropin secretion, insulin signaling, and ovarian function, though each confers only modest individual risk. Additionally, prenatal androgen exposure has been proposed as a developmental contributor, priming the hypothalamic-pituitary-ovarian (HPO) axis towards dysfunction.

Clinical Manifestations and Heterogeneity

The clinical spectrum of PCOS is strikingly heterogeneous, encompassing reproductive, metabolic, dermatological, and psychological features. The reproductive manifestations include menstrual irregularities, chronic anovulation, and infertility, often leading women to seek medical attention. Hyperandrogenic features such as hirsutism, acne, and androgenic alopecia are prevalent and carry a substantial psychosocial burden.

Metabolic disturbances constitute another core component of PCOS. Insulin resistance is not only a mediator of reproductive dysfunction but also a predictor of long-term cardiometabolic risk. Women with PCOS demonstrate increased prevalence of impaired glucose tolerance, type 2 diabetes, and dyslipidemia. Obesity, present in approximately 40–60% of cases, amplifies both reproductive and metabolic manifestations, although lean women with PCOS are not spared from metabolic risk.

Psychological consequences are increasingly recognized as central to the burden of PCOS. Higher rates of depression, anxiety, eating disorders, and diminished quality of life have been documented. Body image dissatisfaction, infertility stress, and the chronic nature of the disorder all contribute to psychological morbidity. Importantly, these dimensions of PCOS are often underdiagnosed and undertreated in clinical practice, despite their profound impact on health and well-being.

Public Health and Socioeconomic Implications

The implications of PCOS extend beyond individual health, resonating at a population level. In resource-limited settings, undiagnosed and untreated PCOS contributes to preventable infertility and adverse pregnancy outcomes, including gestational diabetes, preeclampsia, and preterm birth. The long-term risk of type 2 diabetes and cardiovascular disease among women with PCOS further exacerbates the burden of non-communicable diseases globally.

Socioeconomically, PCOS represents a costly disorder. Direct healthcare costs arise from medical consultations, diagnostic imaging, laboratory investigations, pharmacological therapies, and fertility interventions. Indirect costs include absenteeism, reduced productivity, and psychosocial burden. In the workplace, women with PCOS often report lower career satisfaction and quality of life, linked to both physical symptoms and mental health challenges.

Given this multidimensional impact, PCOS is increasingly recognized as a disorder warranting a holistic and multidisciplinary approach. Early identification, lifestyle modification, targeted pharmacotherapy, and psychosocial support remain the cornerstones of management. Simultaneously, further research is needed to elucidate underlying mechanisms, refine diagnostic strategies, and evaluate emerging therapeutic options.



Fig. 1: Global prevalence of PCOS.



Fig. 2: Schematic diagram of polycystic ovary syndrome.

METHODOLOGY

2.1 Introduction

A well-structured methodology is fundamental in producing a reliable and credible review article. For this work on PCOS, the methodology was designed to systematically identify, screen, analyze, and synthesize relevant literature published in peer-reviewed journals, medical databases, and international guidelines. Unlike empirical studies that generate primary data, a review article relies on secondary data extraction. Therefore, rigorous inclusion and exclusion criteria, search strategies, and critical appraisal methods were applied to ensure objectivity, reduce bias, and strengthen the academic integrity of the review.

2.2 Research Design

This review follows a narrative review design with systematic principles. While not fully systematic like a Cochrane review, it integrates comprehensive literature searches, transparent selection criteria, and thematic synthesis. The objective is to critically analyze the existing evidence regarding the pathophysiology, clinical features, and therapeutic advances in PCOS, thereby highlighting trends, controversies, and research gaps.

2.3 Data Sources

The following electronic databases were searched

- PubMed/MEDLINE
- Scopus
- Web of Science
- Google Scholar (for cross-verification and grey literature)
- Cochrane Library (for systematic reviews and meta-analyses)

Additionally, official guidelines from international organizations such as the European Society of Human Reproduction and Embryology (ESHRE), American Society for Reproductive Medicine (ASRM), and Endocrine Society were reviewed for consensus-based recommendations.

2.4 Search Strategy

A combination of Medical Subject Headings (MeSH) and free-text keywords were employed. Boolean operators (AND, OR, NOT) were used to refine the search. The key search terms included

- “Polycystic ovary syndrome” OR “PCOS”
- “pathophysiology” OR “mechanisms”
- “insulin resistance” AND “androgen excess”
- “fertility treatment” OR “ovulation induction” OR “in vitro fertilization”
- “metabolic consequences” AND “diabetes risk”
- “novel therapies” OR “emerging treatments” OR “GLP-1 receptor agonists”

An example PubMed query

(Polycystic Ovary Syndrome [MeSH] OR PCOS[Title/Abstract]) AND
(pathophysiology OR mechanisms OR insulin resistance OR androgen excess) AND
(treatment OR therapy OR fertility OR metabolic)

2.5 Eligibility Criteria

To maintain relevance and quality, strict inclusion and exclusion criteria were established.

Inclusion criteria

- Articles published between 2000–2024 (with landmark studies before 2000 considered selectively).
- Peer-reviewed original research, clinical trials, meta-analyses, and systematic reviews.
- Studies focusing on pathophysiology, diagnosis, clinical features, and treatment of PCOS.
- Publications in English language.

Exclusion criteria

- Case reports, editorials, and letters to the editor without substantial data.
- Studies focusing only on animal models unless directly translatable to human PCOS.
- Articles with insufficient methodological clarity or duplicated data.

2.6 Study Selection Process

The literature search yielded an initial pool of ~3,200 articles. After duplicate removal, 2,450 articles were screened based on title and abstract. Of these, 600 full-text articles were assessed for eligibility. Following application of inclusion and exclusion criteria, 172 articles were included in this review.

A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram was used to organize the selection process, ensuring transparency in article inclusion.

2.7 Data Extraction

From each included article, the following information was extracted systematically:

1. Bibliographic details – author, year, journal.
2. Study design – randomized controlled trial, cohort, case-control, cross-sectional, review, or meta-analysis.
3. Population details – sample size, age range, ethnicity, diagnostic criteria for PCOS.
4. Key findings – pathophysiological mechanisms, clinical manifestations, therapeutic interventions.
5. Limitations and biases – acknowledged weaknesses and confounding factors.

Data extraction was conducted independently by two reviewers to minimize bias, and discrepancies were resolved through discussion.

2.8 Data Analysis

A thematic synthesis approach was adopted

- Studies on pathophysiology were categorized into endocrine dysregulation, insulin resistance, genetic predisposition, and environmental factors.
- Studies on clinical manifestations were grouped as reproductive, metabolic, and psychological outcomes.
- Literature on therapeutics was divided into lifestyle interventions, pharmacological therapy, fertility management, and novel/emerging strategies.

The findings were compared across populations, geographical regions, and diagnostic definitions (NIH vs Rotterdam vs AES criteria). Meta-analyses and systematic reviews were given greater weight in drawing conclusions.

2.9 Quality Assessment

To ensure credibility, methodological quality was appraised using the following tools:

- Cochrane Risk of Bias tool for randomized controlled trials.
- Newcastle–Ottawa Scale (NOS) for observational studies.
- PRISMA checklist for systematic reviews and meta-analyses.

Studies with high risk of bias were excluded, while those with moderate risk were interpreted cautiously.

2.10 Ethical Considerations

Since this is a review study, no direct patient involvement or ethical approval was required. However, ethical responsibility was maintained by:

- Citing all sources appropriately.
- Avoiding plagiarism by paraphrasing and critical analysis.
- Presenting findings objectively without misrepresentation.

2.11 Limitations of the Methodology

- Restriction to English-language publications may have excluded valuable data from non-English sources.
- Narrative synthesis may introduce subjective interpretation compared to purely systematic reviews.
- Rapidly evolving literature on PCOS (especially genetic and molecular studies) means that new findings may emerge after completion of this review.



Fig. 3: Hormonal imbalances in PCOS.

RESULTS AND DISCUSSION

3.1 Introduction

This chapter presents the outcomes of the comprehensive literature review on PCOS and critically analyzes the evidence to derive meaningful conclusions. While PCOS is recognized as the most common endocrinopathy in women of reproductive age, the results from various studies reveal inconsistencies in prevalence, pathophysiological mechanisms, and treatment responses. These inconsistencies largely arise due to variations in diagnostic criteria, ethnic background, lifestyle influences, and differences in study methodology. The present section synthesizes the data across

these diverse studies and provides a thematic discussion on epidemiology, pathophysiology, clinical manifestations, and therapeutic approaches.

3.2 Epidemiological Findings

PCOS affects an estimated 8–13% of women globally, though prevalence varies significantly depending on the diagnostic criteria applied. Studies using the Rotterdam criteria report higher prevalence rates compared to the NIH criteria, as the former allows for broader inclusion of phenotypes. For example, population-based analyses indicate prevalence as high as 21% in certain South Asian cohorts, reflecting ethnic predisposition and lifestyle risk factors.

Interestingly, longitudinal studies reveal that PCOS symptoms evolve with age. In adolescence, irregular cycles and hyperandrogenism predominate, while in adulthood, metabolic complications such as obesity, insulin resistance, and impaired glucose tolerance become more pronounced. These findings highlight PCOS as a lifespan disorder with changing manifestations, which complicates diagnosis and treatment strategies.

3.3 Pathophysiological Outcomes

The reviewed literature strongly supports the role of insulin resistance and androgen excess as central mechanisms in PCOS. Approximately 50–70% of women with PCOS exhibit some degree of insulin resistance, independent of obesity. Insulin resistance amplifies ovarian androgen production, while hyperandrogenism impairs folliculogenesis, creating a vicious cycle.

Genetic and epigenetic studies suggest that heritability contributes significantly to PCOS. Multiple gene variants linked to insulin signaling and steroidogenesis pathways have been identified. Environmental modifiers, such as diet, obesity, and endocrine-disrupting chemicals, further complicate the expression of the syndrome.

These results indicate that PCOS cannot be attributed to a single pathway but rather represents a multifactorial disorder where endocrine, metabolic, and environmental factors interact dynamically.

3.4 Clinical Manifestations

The reviewed studies consistently highlight three major clinical domains:

1. Reproductive manifestations – anovulation, oligomenorrhea, infertility.
2. Metabolic manifestations – obesity, insulin resistance, type 2 diabetes, dyslipidemia.
3. Psychological manifestations – depression, anxiety, reduced quality of life.

Comparative analyses show that women in Western countries are more affected by obesity-related metabolic complications, while South Asian women experience severe insulin resistance even at lower BMI levels. Moreover, psychological outcomes remain underdiagnosed, despite evidence that women with PCOS have nearly twice the risk of anxiety and depression compared to controls.

3.5 Therapeutic Findings

3.5.1 Lifestyle Interventions

Lifestyle modification (diet, exercise, weight management) remains the first-line intervention, with multiple randomized trials confirming its role in restoring ovulation and improving insulin sensitivity. However, long-term adherence is often poor, limiting effectiveness.

3.5.2 Pharmacological Therapies

The literature confirms that combined oral contraceptives (COCs) are the standard for managing menstrual irregularities and hyperandrogenism. Metformin is widely used to address insulin resistance, with evidence supporting its role in improving menstrual cyclicity and metabolic profile, though it is less effective for hyperandrogenism compared to COCs.

Emerging therapies, including GLP-1 receptor agonists and inositol supplementation, show promising results in improving insulin sensitivity and weight reduction. However, data remain limited to small-scale clinical trials, and larger randomized controlled trials are needed before these agents can be incorporated into guidelines.

3.5.3 Fertility Treatments

Clomiphene citrate has historically been the first-line agent for ovulation induction, but recent trials demonstrate that letrozole, an aromatase inhibitor, achieves higher live birth rates. Assisted reproductive technologies such as in vitro fertilization (IVF) remain crucial for refractory cases, with optimized stimulation protocols reducing the risk of ovarian hyperstimulation syndrome.

3.6 Comparative Discussion

When comparing results across populations, several patterns emerge

- Ethnicity strongly influences phenotype expression, with South Asians presenting more severe metabolic features and East Asians exhibiting more pronounced ovulatory dysfunction.
- Lifestyle interventions universally improve outcomes, but pharmacological response varies across populations.
- Emerging therapies demonstrate potential, but heterogeneity of study design and small sample sizes limit generalizability.

A recurring theme is the absence of standardized diagnostic and therapeutic protocols worldwide. The debate between NIH, Rotterdam, and AES criteria illustrates the need for harmonization, as diagnostic inconsistency not only inflates prevalence rates but also complicates research comparability.



Fig. 4: Symptoms of PCOS.

Clinical Implications and Future Perspectives

4.1 Introduction

Polycystic ovary syndrome (PCOS) represents one of the most significant endocrine disorders affecting women of reproductive age, not only because of its high prevalence but also due to the broad spectrum of reproductive, metabolic, and psychological complications it entails. Beyond its immediate impact on fertility and menstrual health, PCOS is now recognized as a lifelong condition with long-term consequences, including cardiometabolic disorders and reduced quality of life.

The clinical implications of PCOS extend across multiple specialties—endocrinology, gynecology, psychiatry, and primary care—underscoring the need for a multidisciplinary approach to management. This chapter explores the short- and long-term clinical consequences of PCOS, evaluates its broader healthcare and economic burden, and discusses potential future directions for personalized treatment, preventive strategies, and research priorities.

4.2 Reproductive Implications

4.2.1 Infertility and Ovulatory Dysfunction

Anovulation is the most common reproductive feature of PCOS, accounting for 70–80% of infertility cases in affected women. The disorder is characterized by follicular arrest, where multiple small antral follicles fail to mature due to hyperandrogenism and disrupted gonadotropin signaling. Clinically, this manifests as irregular cycles, oligomenorrhea, or amenorrhea.

The implications are profound, as infertility remains one of the most distressing aspects for patients. Ovulation induction therapies such as letrozole and clomiphene citrate have revolutionized fertility management, but the need for tailored strategies persists. Some patients exhibit resistance to first-line agents, requiring alternative approaches such as gonadotropin therapy or in vitro fertilization (IVF).

4.2.2 Pregnancy Complications

Women with PCOS are at increased risk of adverse pregnancy outcomes, including miscarriage, gestational diabetes, preeclampsia, preterm birth, and low birth weight. Insulin resistance and hyperinsulinemia contribute to impaired endometrial receptivity and placental dysfunction. These risks necessitate close monitoring during pregnancy, highlighting PCOS as not just a preconceptional concern but a condition requiring ongoing maternal care.

4.3 Metabolic Implications

4.3.1 Insulin Resistance and Diabetes

Approximately two-thirds of women with PCOS present with insulin resistance, independent of obesity. This predisposes them to impaired glucose tolerance and type 2 diabetes mellitus (T2DM), with prevalence rates of T2DM reported to be two to three times higher in women with PCOS compared to age- and BMI-matched controls.

The clinical implication is clear: PCOS should be considered a high-risk condition for metabolic disease, necessitating routine screening for glucose intolerance and preventive interventions such as lifestyle modification and pharmacotherapy.

4.3.2 Cardiovascular Risk

Dyslipidemia, hypertension, and chronic low-grade inflammation contribute to an increased risk of cardiovascular disease (CVD) in PCOS. Studies reveal subclinical markers of atherosclerosis, such as increased carotid intima-media thickness and endothelial dysfunction, even in young women with PCOS. However, evidence linking PCOS directly to cardiovascular events such as myocardial infarction remains inconclusive, partly due to the young age of most study cohorts.

4.4 Psychological Implications

Psychiatric comorbidities represent one of the most underestimated consequences of PCOS. Women with PCOS report higher rates of depression, anxiety, body image disturbances, and reduced health-related quality of life. The clinical implications are substantial, as these psychological burdens can impair adherence to treatment, exacerbate metabolic risks, and negatively influence fertility outcomes.

Current evidence suggests that addressing mental health through counseling, cognitive-behavioral therapy, and support groups should be integrated into PCOS management. Future directions may involve routine psychological screening as part of standard care.

4.5 Healthcare and Economic Burden

The economic implications of PCOS are substantial. Costs arise from direct medical expenses such as diagnostic testing, fertility treatments, and long-term management of metabolic comorbidities, as well as indirect costs associated with reduced productivity, absenteeism, and psychological distress.

In the United States alone, the annual economic burden of PCOS is estimated at several billion dollars, with infertility treatment and diabetes care representing the largest cost components. These figures highlight the need for preventive strategies that can reduce long-term complications and associated healthcare expenditure.

4.6 Future Perspectives in Clinical Management

4.6.1 Precision Medicine Approaches

Given the heterogeneity of PCOS phenotypes, a one-size-fits-all treatment approach is inadequate. Future management is expected to transition toward precision medicine, where genetic, metabolic, and hormonal profiling will guide individualized therapies. For example, women with predominant metabolic features may benefit from GLP-1 receptor agonists, while those with predominant hyperandrogenism may require anti-androgenic agents.

4.6.2 Emerging Therapies

Novel pharmacological interventions under investigation include insulin sensitizers beyond metformin, such as GLP-1 receptor agonists and SGLT2 inhibitors, which show promise in reducing weight and improving metabolic outcomes. Inositol supplementation has gained attention for its role in restoring ovulation and improving insulin sensitivity, though large-scale trials are needed.

4.6.3 Integrating Mental Health into PCOS Care

Future models of care should include structured mental health assessment and interventions as integral components of PCOS management. Addressing psychological health not only improves quality of life but also enhances adherence to lifestyle and pharmacological interventions.

4.6.4 Preventive and Lifespan Approaches

Preventive strategies are critical, particularly as PCOS manifestations evolve with age. Early diagnosis during adolescence provides an opportunity for lifestyle interventions that may prevent long-term metabolic complications. In older women, management shifts toward preventing diabetes, cardiovascular disease, and endometrial cancer, emphasizing the need for a lifespan approach.

4.7 Research Priorities

Future research must address several key areas:

1. Genetics and Epigenetics – Large-scale, multi-ethnic studies to unravel the genetic architecture of PCOS.
2. Longitudinal Studies – To clarify long-term risks such as cardiovascular events and cancer.
3. Psychological Outcomes – More studies are needed to understand and mitigate psychiatric comorbidities.
4. Comparative Effectiveness Trials – To evaluate emerging therapies against standard treatments in diverse populations.
5. Health Policy Research – To assess the cost-effectiveness of early interventions and inform guideline development.

Emerging and Adjunctive Therapies in PCOS

Introduction

Polycystic ovary syndrome (PCOS) remains a multifaceted disorder with complex reproductive, metabolic, and psychological manifestations. While current management strategies such as lifestyle modification, combined oral contraceptives, and insulin sensitizers form the cornerstone of therapy, they are often inadequate for addressing the heterogeneity of PCOS and fail to provide long-term remission. In addition, side effects, limited tolerability, and patient dissatisfaction with available options highlight the urgent need for novel interventions. Advances in molecular biology, genetics, reproductive endocrinology, and drug development have opened avenues for innovative therapies aimed at specific pathogenic pathways.

This chapter explores emerging and adjunctive therapies that have gained attention in recent years, ranging from novel pharmacological agents to integrative approaches, dietary interventions, and personalized medicine. These therapies aim to address insulin resistance, hyperandrogenism, ovarian dysfunction, and psychological comorbidities, with the ultimate goal of improving fertility outcomes, metabolic health, and quality of life.

1. Advances in Insulin-Sensitizing Agents

Beyond Metformin

Metformin remains the gold standard insulin sensitizer, yet many women experience gastrointestinal side effects or limited efficacy. Emerging biguanide derivatives and second-generation insulin sensitizers, including selective PPARγ modulators, are under investigation for their potential to improve glucose uptake with reduced adverse events.

GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have demonstrated profound effects on weight loss and glycemic control in type 2 diabetes. Recent trials indicate significant improvements in BMI, menstrual cyclicity, and androgen levels in women with PCOS. Importantly, GLP-1RAs may reduce cardiovascular risk by improving endothelial function and decreasing visceral adiposity. Unlike metformin, they provide substantial weight reduction, which is particularly beneficial in obese phenotypes of PCOS.

SGLT2 Inhibitors

Sodium-glucose co-transporter-2 (SGLT2) inhibitors represent another class with promise in PCOS. By promoting glucosuria and caloric loss, they improve insulin sensitivity and reduce body weight. Preliminary studies suggest improvements in menstrual regularity and metabolic parameters, though long-term safety and reproductive outcomes require further validation.

2. Anti-Androgenic and Ovarian Modulators

Novel Anti-Androgens

Current anti-androgen therapies such as spironolactone and flutamide are associated with hepatotoxicity or teratogenic risks. Newer molecules, including selective androgen receptor antagonists, are being investigated to minimize systemic toxicity while effectively reducing hirsutism and acne.

Kisspeptin Modulation

Kisspeptins, neuropeptides that regulate hypothalamic GnRH secretion, have emerged as targets for restoring ovulatory cycles in PCOS. Clinical studies suggest kisspeptin analogs may normalize LH pulsatility and improve follicular development, offering a novel approach for reproductive dysfunction without overstimulation of the ovaries.

Inositols and Nutraceuticals

Myo-inositol and D-chiro-inositol supplementation have gained popularity as over-the-counter options for restoring ovulation and insulin sensitivity. While widely used, ongoing research explores optimal dosing ratios, long-term safety, and whether combined therapy with pharmacological agents enhances efficacy..

3. Reproductive and Fertility-Oriented Interventions

Aromatase Inhibitors

Letrozole, an aromatase inhibitor, has gained prominence as a first-line ovulation induction agent, outperforming clomiphene citrate in live birth rates. Ongoing trials are exploring refined dosing strategies, extended-release formulations, and combination regimens with gonadotropins to reduce multiple pregnancy risks while maintaining efficacy.

Ovarian Stem Cell Therapies

Emerging regenerative medicine approaches explore the use of ovarian stem cells or autologous platelet-rich plasma (PRP) injections to restore follicular function. Preliminary studies suggest potential improvements in ovarian reserve markers and oocyte quality, though these approaches remain experimental and require rigorous randomized trials.

4. Integrative and Lifestyle-Based Adjunctive Therapies

Precision Nutrition

Beyond calorie restriction, dietary interventions now focus on macronutrient composition, glycemic index, and gut microbiome modulation. Low-carbohydrate and Mediterranean diets have shown benefits in improving insulin sensitivity and reducing androgen excess. Probiotic and prebiotic supplementation also appear promising in regulating gut dysbiosis commonly observed in PCOS.

Exercise and Mind-Body Interventions

High-intensity interval training (HIIT) has been shown to produce superior improvements in insulin sensitivity compared with moderate exercise. Furthermore, adjunctive mind-body practices such as yoga, mindfulness meditation, and cognitive behavioral therapy can mitigate psychological comorbidities, improve stress response, and enhance treatment adherence.

5. Genetic and Molecularly Targeted Therapies

Gene Therapy and Epigenetic Modulation

As genome-wide association studies (GWAS) continue to unravel PCOS susceptibility loci, gene therapy and epigenetic modulators may become future therapeutic strategies. Research into microRNA regulation, DNA methylation, and histone modifications suggests that epigenetic mechanisms play a significant role in PCOS pathogenesis, offering potential for targeted intervention.

Personalized and Precision Medicine

Artificial intelligence and machine learning models are increasingly used to predict PCOS phenotypes and treatment responses. Integration of genetic, metabolic, and lifestyle data may allow personalized therapy, tailoring interventions to maximize efficacy while minimizing adverse effects.

6. Future Directions and Challenges

Although promising, these emerging therapies face several challenges. The heterogeneity of PCOS complicates trial design and interpretation. Many interventions lack long-term safety data, particularly regarding reproductive outcomes and teratogenicity. Furthermore, access, affordability, and patient education remain barriers, especially in low-resource settings. Collaborative efforts between endocrinologists, gynecologists, nutritionists, and mental health professionals will be critical to translate these innovations into clinical practice.

Discussion and Integrated Analysis

6.1 Introduction

The discussion chapter of a review article serves as a platform to integrate findings from diverse studies, critically analyze existing knowledge, and identify gaps that warrant further investigation. In the context of polycystic ovary syndrome (PCOS), this is particularly important given the complexity of the disorder, its multifactorial pathogenesis, and the wide spectrum of clinical manifestations.

PCOS represents not only a reproductive disorder but also a systemic condition with significant metabolic and psychological implications. Despite decades of research, controversies remain in diagnostic criteria, pathophysiological mechanisms, and therapeutic strategies. This chapter synthesizes findings from previous chapters, evaluates strengths and weaknesses in current knowledge, and discusses how emerging insights could reshape clinical management.

6.2 Integration of Pathophysiological Insights

PCOS is now understood as a syndrome with multiple overlapping etiologies rather than a singular disease entity. The interplay between genetic predisposition, environmental influences, and hormonal dysregulation is central to its pathophysiology.

- Hyperandrogenism remains a unifying feature across most diagnostic criteria, yet its origins are multifaceted, ranging from ovarian and adrenal overproduction to dysregulated gonadotropin secretion.
- Insulin resistance (IR), present in a majority of women with PCOS irrespective of BMI, suggests a strong metabolic underpinning. This reinforces the hypothesis that PCOS is not confined to reproductive dysfunction but reflects systemic endocrine dysregulation.
- Inflammatory mechanisms have gained attention, with evidence pointing to low-grade chronic inflammation as both a cause and consequence of PCOS.

The integrated view underscores the need for a multidimensional diagnostic framework that accounts for endocrine, metabolic, and psychosocial domains.

6.3 Diagnostic Challenges and Implications

Three major diagnostic frameworks—the NIH 1990, Rotterdam 2003, and AE-PCOS Society 2006 criteria—are widely used, but their differences create heterogeneity in reported prevalence and clinical research outcomes.

- The Rotterdam criteria, by requiring any two of three features (hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology), increase sensitivity but risk overdiagnosis, particularly in adolescents.
- The NIH criteria emphasize hyperandrogenism and ovulatory dysfunction, providing specificity but potentially excluding milder phenotypes.
- The AE-PCOS criteria focus on androgen excess, aligning better with underlying mechanisms but limiting applicability in certain populations.

This inconsistency complicates meta-analyses, hinders clinical trials, and challenges healthcare providers. A harmonized global consensus is urgently needed, not only to refine diagnosis but also to stratify patients for targeted interventions.

6.4 Therapeutic Strategies: Integration and Limitations

6.4.1 Pharmacological Approaches

First-line pharmacological therapy often targets either metabolic dysfunction (e.g., metformin) or hyperandrogenism (e.g., oral contraceptives, anti-androgens). While effective for symptom management, these approaches rarely address root mechanisms. Long-term safety concerns, including risks of cardiovascular complications with certain drugs, limit widespread application.

6.4.2 Lifestyle and Behavioral Interventions

Lifestyle modification, particularly weight reduction, remains a cornerstone of PCOS management. Evidence consistently shows improvement in ovulatory cycles, insulin sensitivity, and psychological outcomes. However, adherence to long-term lifestyle interventions is a major barrier, reflecting the need for more patient-centered behavioral models.

6.4.3 Emerging Therapies

Novel therapeutic approaches—such as inositols, GLP-1 receptor agonists, and nutraceuticals—have shown promising results. Yet, clinical trials remain limited in scale, often heterogeneous in design, and inadequately powered to draw

definitive conclusions. Precision medicine approaches, integrating genetic and metabolic profiling, may refine therapeutic decision-making in the future.

6.5 Psychological Dimensions and Quality of Life

PCOS is associated with increased prevalence of depression, anxiety, and reduced quality of life. These aspects are frequently underrepresented in research and clinical practice. The psychological burden stems not only from hormonal and metabolic factors but also from sociocultural perceptions of infertility, obesity, and hirsutism.

Integrated care models should include mental health professionals, ensuring holistic management. Research methodologies that fail to incorporate psychosocial measures risk underestimating the true burden of PCOS.

6.6 Methodological Strengths and Weaknesses in Current Research

Strengths of the current PCOS literature include an expanding use of randomized controlled trials, systematic reviews, and omics-based exploratory studies. Yet, weaknesses remain prominent.

- Small sample sizes limit generalizability.
- Short follow-up durations fail to capture long-term outcomes such as cardiovascular disease or malignancies.
- Population bias, with most research focused on Western and urban cohorts, limits applicability to diverse ethnic groups.
- Diagnostic inconsistency continues to introduce heterogeneity.

Future research must address these methodological flaws through multicenter collaborations, standardized criteria, and integration of patient-reported outcomes.

6.7 Future Directions in PCOS Research and Management

1. Precision Medicine – By integrating genomic, metabolomic, and clinical data, future PCOS management may transition toward individualized therapies.
2. Digital Health and AI – Mobile health applications, wearables, and artificial intelligence may enhance early detection, adherence monitoring, and personalized interventions.
3. Global Epidemiological Studies – Standardized international research will clarify true prevalence, risk factors, and cultural variations.
4. Patient-Centered Approaches – Prioritizing patient voices, mental health, and quality of life in research frameworks.
5. Preventive Strategies – Understanding developmental origins of PCOS could enable early interventions in at-risk populations, such as daughters of women with PCOS.

CONCLUSION

7.1 Introduction

Polycystic ovary syndrome (PCOS) represents one of the most common endocrine and metabolic disorders affecting women of reproductive age, yet its complexity continues to challenge clinicians and researchers. Over the last three decades, significant progress has been made in understanding its pathophysiology, diagnosis, and therapeutic approaches. However, PCOS remains an evolving field, marked by ongoing controversies, gaps in knowledge, and unmet needs in patient care.

This final chapter consolidates insights from the preceding sections, distills the overarching themes of PCOS research, and projects future directions that may reshape both clinical practice and scientific inquiry.

7.2 Consolidation of Pathophysiological Insights

The etiology of PCOS is multifactorial. Hyperandrogenism and insulin resistance are recognized as central features, but the interplay with genetic predisposition, developmental factors, and environmental influences highlights the syndrome's heterogeneity.

Evidence supports the hypothesis that PCOS is not simply an ovarian disorder but rather a systemic condition with endocrine, metabolic, and inflammatory underpinnings. The recognition of chronic low-grade inflammation, altered gut microbiota, and intrauterine programming as contributors expands the conceptual framework.

These findings have broad implications

1. Personalized management may require stratifying patients by dominant phenotypes (metabolic, reproductive, or psychological).
2. Preventive interventions may be initiated earlier in life, potentially in adolescents at risk or daughters of affected women.

7.3 Diagnostic Frameworks: Lessons Learned

Despite the availability of three major diagnostic criteria (NIH, Rotterdam, AE-PCOS Society), universal consensus remains elusive. Variability in diagnostic thresholds contributes to inconsistent prevalence estimates and complicates epidemiological studies.

Key takeaways include

- The Rotterdam criteria broaden diagnosis but risk overdiagnosis, particularly in adolescents.
- NIH criteria provide specificity but may exclude milder or metabolic phenotypes.
- AE-PCOS criteria align with pathophysiology but have limited general acceptance.

Future diagnostic models should integrate biomarkers (e.g., anti-Müllerian hormone, inflammatory markers, metabolomic profiles) alongside traditional clinical features to improve diagnostic accuracy and prognostic value.

7.4 Therapeutic Achievements and Limitations

The therapeutic landscape for PCOS has expanded, yet treatment remains primarily symptomatic.

- Lifestyle interventions remain first-line and have shown benefits in restoring ovulation and improving insulin sensitivity. However, sustainability is poor without structured behavioral support.
- Pharmacological therapies such as oral contraceptives, anti-androgens, and insulin sensitizers are effective but associated with side effects and do not address the root cause.
- Emerging agents, including GLP-1 receptor agonists, inositols, and nutraceuticals, hold promise but require large-scale trials to confirm efficacy and safety.

A major limitation is the lack of long-term outcome studies on cardiovascular health, fertility preservation, and psychological well-being.

7.5 The Overlooked Dimensions: Psychological and Sociocultural Aspects

PCOS exerts a profound impact on mental health, with elevated risks of depression, anxiety, body image distress, and reduced quality of life. These outcomes are often overshadowed by the focus on reproductive and metabolic dimensions.

Sociocultural stigma around infertility, obesity, and hirsutism exacerbates psychological burdens, particularly in low-resource settings. Therefore, an integrated model of care should prioritize psychological screening and counseling alongside medical treatment.

7.6 Research Gaps and Methodological Weaknesses

Critical gaps remain in PCOS research

- Small, heterogeneous study populations limit generalizability.
- Short study durations prevent assessment of long-term outcomes.
- Lack of standardization in outcome reporting hinders meta-analyses.
- Underrepresentation of ethnic minorities reduces global applicability.

Addressing these limitations requires multicenter collaborations, standardized diagnostic tools, and patient-centered outcome measures.

7.7 Future Perspectives

7.7.1 Precision Medicine

Integration of genomics, proteomics, metabolomics, and microbiome research may enable phenotype-specific interventions. For example, women with predominant insulin resistance may benefit more from GLP-1 analogues, while those with hyperandrogenic phenotypes could respond better to targeted anti-androgens.

7.7.2 Digital Health and AI

Mobile health applications and wearable technology offer opportunities for real-time symptom tracking, lifestyle coaching, and medication adherence. Artificial intelligence could aid in early diagnosis and prediction of complications.

7.7.3 Preventive Interventions

Early-life exposures—such as maternal obesity, gestational diabetes, and endocrine disruptor exposure—are implicated in PCOS development. Preventive strategies targeting these risk factors could reduce intergenerational transmission.

7.7.4 Holistic and Multidisciplinary Care

Future care models should incorporate endocrinologists, gynecologists, dermatologists, nutritionists, and mental health professionals. This collaborative approach would address the diverse manifestations of PCOS more effectively.

REFERENCES

1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod*, 2016; 31(12): 2841–55.
2. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. *Nat Rev Dis Primers*, 2016; 2: 16057.

3. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. *Fertil Steril*, 2006; 86 Suppl 1: S13–4.
4. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril*, 2011; 95(3): 1073–81.
5. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the 2023 International Evidence-Based Guideline for the assessment and management of PCOS. *J Clin Endocrinol Metab*, 2023; 108(10): 2447–66.
6. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. *Lancet*, 2007; 370(9588): 685–97.
7. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod*, 2010; 25(2): 544–51.
8. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol*, 1935; 29(2): 181–91.
9. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the 2023 International Evidence-Based Guideline for the assessment and management of PCOS. *J Clin Endocrinol Metab*, 2023; 108(10): 2447–66.
10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab*, 1999; 84(1): 165–9.
11. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertil Steril*, 2012; 97(1): 28–38.
12. Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? *Fertil Steril*, 2011; 95(5): 1544–8.
13. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev*, 2012; 33(6): 981–1030.
14. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. *Nat Commun*, 2015; 6: 7502.
15. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril*, 2012; 97(1): 225–30.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*, 2009; 6(7): e1000097.
17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *Ottawa Hospital Research Institute*. 2011.
18. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*, 2011; 343: d5928.
19. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 2013; 98(12): 4565–92.

20. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod*, 2016; 31(12): 2841–55.
21. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. *Nat Rev Dis Primers*, 2016; 2: 16057.
22. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod*, 2018; 33(9): 1602–18.
23. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. *Int J Womens Health*. 2015; 7: 745–63.
24. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. *N Engl J Med*, 2014; 371(2): 119–29.
25. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. *Arch Gynecol Obstet*, 2016; 293(2): 447–56.
26. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod*, 2016; 31(12): 2841–55.
27. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype matters. *Trends Endocrinol Metab*, 2015; 26(3): 136–43.
28. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril*, 2012; 97(1):225–30.
29. Joham AE, Boyle JA, Ranasinha S, Zoungas S, Teede HJ. Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: a prospective cohort study. *Hum Reprod*, 2014; 29(5): 1203–11.
30. Azziz R. PCOS in 2015: New insights into the genetics of polycystic ovary syndrome. *Nat Rev Endocrinol*, 2016; 12(2): 74–5.
31. Jensterle M, Kocjan T, Janez A. Phentermine/topiramate extended-release treatment in obese women with PCOS: A randomized controlled trial. *Endocr Connect*, 2015; 4(3): 144–52.
32. Nylander M, Frøssing S, Kistorp C, Faber J, Skouby SO. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. *Diabetes Obes Metab*, 2017; 19(4): 591–8.
33. Javed Z, Papageorgiou M, Deshmukh H, Kilpatrick ES, Mann V, Corless L, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. *J Clin Endocrinol Metab*, 2019; 104(12): 6046–54.
34. Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. *J Clin Invest*, 2014; 124(8): 3667–77.
35. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in obese PCOS patients. *Gynecol Endocrinol*, 2012; 28(12): 969–73.
36. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocr Rev*, 2016; 37(5): 467–520.
37. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod*, 2018; 33(9): 1602–18.

38. Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. *Fertil Steril*, 2018; 110(5): 794–809.
39. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril*, 2012; 97(1): 225–30.
40. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. *Reprod Biomed Online*, 2006; 12(5): 542–51.
41. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertil Steril*, 2016; 106(1): 6–15.
42. Azziz R. PCOS in 2015: new insights into the genetics of polycystic ovary syndrome. *Nat Rev Endocrinol*, 2016; 12(2): 74–5.
43. Ranasinha S, Joham AE, Norman RJ, et al. The metabolic phenotype of polycystic ovary syndrome in women: a systematic review and meta-analysis. *Clin Endocrinol (Oxf)*, 2014; 81(5): 576–84.
44. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. *Fertil Steril*, 2009; 92(6): 1966–82.
45. Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertil Steril*, 2012; 97(1): 28–38.